Our Firm has heard from numerous individuals who allegedly suffered uncontrollable bleeding and other serious complications due to their use of Xarelto.
New York, New York (PRWEB) October 25, 2014
The proposed consolidation of all federally-filed Xarelto lawsuits (http://www.thexareltolawsuit.com/) will be addressed in December, when the U.S. Judicial Panel on Multidistrict Litigation (JPML) convenes its next hearing session. According to a Hearing Session Order issued by the Panel on October 22nd, Oral Arguments on the matter will be heard on December 4, 2014, in Charleston, South Carolina. The Hearing Session will begin at 9:30 a.m. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our Firm has heard from numerous individuals who allegedly suffered uncontrollable bleeding and other serious complications due to their use of Xarelto. The Xarelto litigation has the potential to be large, and all parties may benefit from the type of consolidation being considered by the JPML,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
According to court documents, the consolidation of federally –filed Xarelto claims was proposed by six plaintiffs who have filed lawsuits claiming the use of the blood thinner increases the risk for life-threatening internal bleeding and other serious injuries. According to a Motion they filed with the JPML on October 9th, at least 21 Xarelto lawsuits that put forth similar allegations are now pending in federal courts throughout the U.S. The Motion also points out that Xarelto has been implicated in hundreds of adverse events reported to the U.S. Food & Drug Administration (FDA), suggesting that thousands of additional claims could be filed in the future. Plaintiffs have proposed the U.S. District Court, Southern District of Illinois as an ideal venue for the Xarelto multidistrict litigation.
Xarelto was approved by the FDA in July 2011, and is now indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. *
In January 2013, the Institute for Safe Medicine Practices reported that the FDA had logged more than 2,000 adverse events involving Xarelto, including 151 fatalities.**
Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.
*fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
**ismp.org/quarterwatch/pdfs/2012Q2.pdf, ISMP, January 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP